[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100525232":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":26,"locations":33,"responsibleParty":60,"collaborators":64,"id":68,"slug":69,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":72,"acronym":31,"eligibilityCriteria":73,"healthyVolunteers":70,"sex":74,"minAge":75,"maxAge":76,"enrollmentInfo":77,"targetDuration":31,"studyType":80,"phases":81,"briefSummary":83,"conditions":84,"keywords":86,"overallStatus":35,"whyStopped":31,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"University of Kentucky","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Telavancin","EXPERIMENTAL","Subjects receiving telavancin for pharmacokinetic sampling",[13],"Drug: Telavancin Injection",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Telavancin Injection","Telavancin 10mg\u002Fkg (maximum 1000mg) administered intravenously over 60 minutes (through a central venous catheter whenever available).",[9],[21],"Vibativ",[23],{"name":24,"affiliation":5,"role":25},"Aaron M Cook, PharmD","PRINCIPAL_INVESTIGATOR",[27],{"name":28,"role":29,"phone":30,"phoneExt":31,"email":32},"Aaron Cook, PharmD","CONTACT","859-323-9258",null,"amcook0@email.uky.edu",[34],{"facility":5,"status":35,"city":36,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"RECRUITING","Lexington","Kentucky","40536","United States","US",{"type":42,"coordinates":43},"Point",[44,45],-84.47772,37.98869,{"lat":45,"lon":44},[48,49,52,54,56,58],{"name":24,"role":29,"phone":30,"phoneExt":31,"email":32},{"name":50,"role":51,"phone":31,"phoneExt":31,"email":31},"David Burgess, PharmD","SUB_INVESTIGATOR",{"name":53,"role":51,"phone":31,"phoneExt":31,"email":31},"David Dornbos, MD",{"name":55,"role":51,"phone":31,"phoneExt":31,"email":31},"Justin Fraser, MD",{"name":57,"role":51,"phone":31,"phoneExt":31,"email":31},"Kevin Hatton, MD, PhD",{"name":59,"role":51,"phone":31,"phoneExt":31,"email":31},"Ryan Mynatt, PharmD",{"type":61,"investigatorFullName":62,"investigatorTitle":63,"investigatorAffiliation":5,"oldNameTitle":31,"oldOrganization":31},"SPONSOR_INVESTIGATOR","Aaron Cook","Professor",[65],{"name":66,"class":67},"Cumberland Pharmaceuticals","INDUSTRY","100525232","phase-4-telavancin-blood-and-cerebrospinal-fluid-concentrations-in-patients-with-external-ventricular-drainage-100525232",false,"NCT06119061","Telavancin Blood and Cerebrospinal Fluid Concentrations in Patients With External Ventricular Drainage","Inclusion Criteria:\n\n* Adult aged 18-85 years\n* Actively draining ventriculostomy\n\nExclusion Criteria:\n\n* history of hypersensitivity to telavancin or similar agents\n* reduced renal function (estimated creatinine clearance \\\u003C 50\u002Fml) at the time of consent\n* severe anemia (hemoglobin \\\u003C 7gm\u002Fdl)\n* vulnerable population (pregnant, prisoner)\n* concomitant antimicrobial therapy","ALL","18 Years","85 Years",{"count":78,"type":79},20,"ESTIMATED","INTERVENTIONAL",[82],"PHASE4","The proposed study aims to evaluate the CNS penetration of telavancin in a critically ill population using cerebrospinal fluid (CSF) drawn from external ventricular drains (EVDs). Patients with EVDs were chosen as the target population because they frequently require prolonged admission to the intensive care unit and drainage of CSF in order to prevent hydrocephalus. The estimated sample size is 20 subjects. This is a prospective cohort of patients with SAH. Patients will be included if they have an in-dwelling EVD, aged 18-85 years old.\n\nSubjects will receive telavancin 10mg\u002Fkg (maximum 1000mg) every 24 hours for 3 consecutive doses. Serial serum and CSF samples will be obtained. An 8-hour urine collection will be completed on study day 2 in order to define the patient's measured creatinine clearance.",[85],"Subarachnoid Hemorrhage, Aneurysmal",[87,88],"pharmacokinetics","augmented renal clearance","2025-12-23",{"date":91,"type":92},"2025-12-26","ACTUAL",{"date":94,"type":92},"2024-07-02",{"date":96,"type":79},"2026-12",{"name":62,"class":6},1]